Knockdown of long non‑coding RNA LINC00152 increases cisplatin sensitivity in ovarian cancer cells

Zou,Hanxue; Li,Hongxia

doi:10.3892/etm.2019.8066

Knockdown of long non‑coding RNA LINC00152 increases cisplatin sensitivity in ovarian cancer cells

Authors:
- Hanxue Zou
- Hongxia Li
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Beijing Shijitan Hospital of Capital Medical University, Beijing 100038, P.R. China
Published online on: September 30, 2019 https://doi.org/10.3892/etm.2019.8066
Pages: 4510-4516
Copyright: © Zou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Drug resistance severely limits the effectiveness of chemotherapeutic treatment in ovarian cancer. The present study aimed to investigate the role of long non‑coding RNA LINC00152 (LINC00152) in the cisplatin resistance of ovarian cancer. The expression level of LINC00152 was significantly increased in the ovarian cancer CoC1 and CoC1/DDP cell lines compared with the normal ovarian IOSE‑80 cell line. To further investigate the function of LINC00152, small interfering RNAs (siRNAs) targeting LINC00152 were transfected into COC1 and COC1/DDP cells, which were subsequently treated with varying concentrations of cisplatin. The results revealed that LINC00152 silencing increased the apoptotic rates and enhanced the chemosensitivity of CoC1 and CoC1/DDP cells to cisplatin. Furthermore, downregulation of LINC00152 significantly decreased Bcl‑2, and increased Bax and cleaved caspase‑3 expression levels. Additionally, LINC00152 silencing decreased the expression of multidrug resistance‑associated gene 1 (MDR1), multidrug resistance‑associated protein 1 (MRP1) and glutathione S‑transferase π (GSTπ). Collectively, the data demonstrated that LINC00152 knockdown increased the chemosensitivity of epithelial ovarian cancer cells to cisplatin by increasing apoptosis and decreasing the expression levels of MDR1, MRP1 and GSTπ.

View Figures

View References

1	Mezzanzanica D: Ovarian cancer: A molecularly insidious disease. Chin J Cancer. 34:1–3. 2015. View Article : Google Scholar : PubMed/NCBI
2	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
3	Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M and Kroemer G: Molecular mechanisms of cisplatin resistance. Oncogene. 31:1869–1883. 2012. View Article : Google Scholar : PubMed/NCBI
4	Rancoule C, Guy JB, Vallard A, Ben Mrad M, Rehailia A and Magné N: 50th anniversary of cisplatin. Bull Cancer. 104:167–176. 2017. View Article : Google Scholar : PubMed/NCBI
5	Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL and Burger RA; Gynecologic Oncology Group, : Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 354:34–43. 2006. View Article : Google Scholar : PubMed/NCBI
6	Tomao F, Marchetti C, Romito A, Di Pinto A, Di Donato V, Capri O, Palaia I, Monti M, Muzii L and Benedetti Panici P: Overcoming platinum resistance in ovarian cancer treatment: From clinical practice to emerging chemical therapies. Expert Opin Pharmacother. 18:1443–1455. 2017. View Article : Google Scholar : PubMed/NCBI
7	Jarroux J, Morillon A and Pinskaya M: History, discovery, and classification of lncRNAs. Adv Exp Med Biol. 1008:1–46. 2017. View Article : Google Scholar : PubMed/NCBI
8	Wieczorek E and Reszka E: mRNA, microRNA and lncRNA as novel bladder tumor markers. Clin Chim Acta. 477:141–153. 2018. View Article : Google Scholar : PubMed/NCBI
9	Marchese FP, Raimondi I and Huarte M: The multidimensional mechanisms of long noncoding RNA function. Genome Biol. 18:2062017. View Article : Google Scholar : PubMed/NCBI
10	Hu B, Zhang H, Wang Z, Zhang F, Wei H and Li L: LncRNA CCAT1/miR-130a-3p axis increases cisplatin resistance in non-small-cell lung cancer cell line by targeting SOX4. Cancer Biol Ther. 18:974–983. 2017. View Article : Google Scholar : PubMed/NCBI
11	Wu Y and Wang H: LncRNA NEAT1 promotes dexamethasone resistance in multiple myeloma by targeting miR-193a/MCL1 pathway. J Biochem Mol Toxicol. 32:e220082018. View Article : Google Scholar
12	Chen P, Fang X, Xia B, Zhao Y, Li Q and Wu X: Long noncoding RNA LINC00152 promotes cell proliferation through competitively binding endogenous miR-125b with MCL-1 by regulating mitochondrial apoptosis pathways in ovarian cancer. Cancer Med. 7:4530–4541. 2018. View Article : Google Scholar : PubMed/NCBI
13	Ma J, Yang J, Wang C, Zhang N, Dong Y, Wang C, Wang Y and Lin X: Emodin augments cisplatin cytotoxicity in platinum-resistant ovarian cancer cells via ROS-dependent MRP1 downregulation. Biomed Res Int. 2014:1076712014. View Article : Google Scholar : PubMed/NCBI
14	Zhang T, Guan M, Jin HY and Lu Y: Reversal of multidrug resistance by small interfering double-stranded RNAs in ovarian cancer cells. Gynecol Oncol. 97:501–507. 2005. View Article : Google Scholar : PubMed/NCBI
15	Wang F, Zhu Y, Fang S, Li S and Liu S: Effect of lanthanum chloride on tumor growth and apoptosis in human ovarian cancer cells and xenograft animal models. Exp Ther Med. 16:1143–1148. 2018.PubMed/NCBI
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
17	Pogge von Strandmann E, Reinartz S, Wager U and Müller R: Tumor-Host cell interactions in ovarian cancer: Pathways to therapy failure. Trends Cancer. 3:137–148. 2017. View Article : Google Scholar : PubMed/NCBI
18	Kujawa KA and Lisowska KM: Ovarian cancer-from biology to clinic. Postepy Hig Med Dosw (Online). 69:1275–1290. 2015.(In Polish). View Article : Google Scholar : PubMed/NCBI
19	Mitra R, Chen X, Greenawalt EJ, Maulik U, Jiang W, Zhao Z and Eischen CM: Decoding critical long non-coding RNA in ovarian cancer epithelial-to-mesenchymal transition. Nat Commun. 8:16042017. View Article : Google Scholar : PubMed/NCBI
20	Worku T, Bhattarai D, Ayers D, Wang K, Wang C, Rehman ZU, Talpur HS and Yang L: Long non-coding RNAs: The new horizon of gene regulation in ovarian cancer. Cell Physiol Biochem. 44:948–966. 2017. View Article : Google Scholar : PubMed/NCBI
21	Martini P, Paracchini L, Caratti G, Mello-Grand M, Fruscio R, Beltrame L, Calura E, Sales G, Ravaggi A, Bignotti E, et al: lncRNAs as novel indicators of patients' prognosis in stage I epithelial ovarian cancer: A retrospective and multicentric study. Clin Cancer Res. 23:2356–2366. 2017. View Article : Google Scholar : PubMed/NCBI
22	Xu J, Wu J, Fu C, Teng F, Liu S, Dai C, Shen R and Jia X: Multidrug resistant lncRNA profile in chemotherapeutic sensitive and resistant ovarian cancer cells. J Cell Physiol. 233:5034–5043. 2018. View Article : Google Scholar : PubMed/NCBI
23	Xu QF, Tang YX and Wang X: LncRNA EBIC promoted proliferation, metastasis and cisplatin resistance of ovarian cancer cells and predicted poor survival in ovarian cancer patients. Eur Rev Med Pharmacol Sci. 22:4440–4447. 2018.PubMed/NCBI
24	Wang Y, Wang H, Song T, Zou Y, Jiang J, Fang L and Li P: HOTAIR is a potential target for the treatment of cisplatin-resistant ovarian cancer. Mol Med Rep. 12:2211–2216. 2015. View Article : Google Scholar : PubMed/NCBI
25	Zhang C, Wang M, Shi C, Shi F and Pei C: Long non-coding RNA Linc00312 modulates the sensitivity of ovarian cancer to cisplatin via the Bcl-2/Caspase-3 signaling pathway. Biosci Trends. 12:309–316. 2018. View Article : Google Scholar : PubMed/NCBI
26	Yue B, Cai D, Liu C, Fang C and Yan D: Linc00152 Functions as a competing endogenous RNA to confer oxaliplatin resistance and holds prognostic values in colon cancer. Mol Ther. 24:2064–2077. 2016. View Article : Google Scholar : PubMed/NCBI
27	Guo F, Cao Z, Guo H and Li S: The action mechanism of lncRNA-HOTAIR on the drug resistance of non-small cell lung cancer by regulating Wnt signaling pathway. Exp Ther Med. 15:4885–4889. 2018.PubMed/NCBI
28	Li H, Yuan X, Yan D, Li D, Guan F, Dong Y, Wang H, Liu X and Yang B: Long non-coding RNA MALAT1 decreases the sensitivity of resistant glioblastoma cell lines to temozolomide. Cell Physiol Biochem. 42:1192–1201. 2017. View Article : Google Scholar : PubMed/NCBI
29	Zhu J, Zhang R, Yang D, Li J, Yan X, Jin K, Li W, Liu X, Zhao J, Shang W and Yu T: Knockdown of long non-coding RNA XIST inhibited doxorubicin resistance in colorectal cancer by upregulation of miR-124 and downregulation of SGK1. Cell Physiol Biochem. 51:113–128. 2018. View Article : Google Scholar : PubMed/NCBI